Journal of Clinical Pathology and Laboratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Clinical Pathology and Laboratory Medicine (2023) Volume 5, Issue 5

Phage therapy: A new frontier in combating bacterial infections

Sandra Elizabeth*

Department of Clinical Pathology, University of Amsterdam, Netherlands

*Corresponding Author:
Sandra Elizabeth
Department of Clinical Pathology, University of Amsterdam, Netherlands
University of Amsterdam

Received:26-Sept-2023, Manuscript No. AACPLM-23-115533; Editor assigned: 28-Sept-2023, PreQC No. AACPLM-23-115533(PQ); Reviewed:11-Oct-2023, QC No. AACPLM-23-115533; Revised:16-Oct-2023, Manuscript No. AACPLM-23-115533(R); Published:23-Oct-2023, DOI:10.35841/ aacplm-5.5.175

Citation: Elizabeth S. Phage therapy: A new frontier in combating bacterial infections. J Clin Path Lab Med. 2023;5(5):175


In a world where antibiotic resistance is on the rise, scientists are turning to a centuries-old, yet cutting-edge, approach to combat bacterial infections: phage therapy. Phages, short for bacteriophages, are viruses that specifically target and infect bacteria. This article explores the concept of phage therapy, its history, current applications, and its potential to revolutionize the way we treat bacterial diseases [1].

Phage therapy has a rich history dating back to the early 20th century when Georgian microbiologist Félix d'Hérelle and Canadian scientist Frederick Twort independently discovered bacteriophages. D'Hérelle coined the term "bacteriophage," meaning "bacteria eater." This ground-breaking discovery laid the foundation for the development of phage therapy. Phage’s are natural predators of bacteria. They infect bacterial cells, reproduce within them, and ultimately cause the bacterial cell to burst, releasing a new generation of phages. Unlike antibiotics, which can affect a broad spectrum of bacteria (including beneficial ones), phages are highly specific to particular bacterial strains, sparing beneficial microorganisms [2].

Human Health: Phage therapy is being explored as a potential treatment for bacterial infections that are resistant to antibiotics, including multidrug-resistant bacteria like Methicillin-resistant Staphylococcus Aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria. Food Safety: Phages can be used to control harmful bacteria in the food industry, reducing the risk of foodborne illnesses. Agriculture: Phage therapy has the potential to combat bacterial plant pathogens, reducing the need for chemical pesticides and promoting sustainable agriculture. Environmental Remediation: Phages can be employed to control bacteria responsible for environmental pollution, such as oil spills [3].

Phages are highly specific, meaning the right phage must be identified for each bacterial strain. This can be time-consuming. Regulation: Regulatory frameworks for phage therapy vary by country, making it challenging to standardize and commercialize. Resistance: Just as bacteria can develop resistance to antibiotics, they can also develop resistance to phages [4].

Phage Stability: Phages can be fragile and sensitive to environmental factors, which can affect their efficacy. Despite challenges, phage therapy is gaining momentum as a viable alternative to antibiotics. Advances in genomics and biotechnology are making it easier to identify and produce specific phages. Researchers are also investigating phage-antibiotic combination therapies to enhance treatment outcomes [5].


Phage therapy represents a promising avenue for addressing the growing threat of antibiotic resistance. By harnessing the natural predatory abilities of bacteriophages, scientists are pioneering a new era in the fight against bacterial infections. While challenges exist, ongoing research and technological advancements hold the potential to unlock the full therapeutic potential of phages, offering hope for more effective and targeted treatments in the future.


  1. Berchieri Jr A, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res Microbiol. 1991;142(5):541-9.
  2. Indexed at, Google Scholar, Cross Ref

  3. Ramesh V, Fralick JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe. 1999;5(2):69-78.
  4. Indexed at, Google Scholar, Cross Ref

  5. Capparelli R, Ventimiglia I, Roperto S, et al. Selection of an Escherichia coli O157: H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin Microbiol Infect. 2006 12(3):248-53.
  6. Indexed at, Google Scholar, Cross Ref

  7. Huff WE, Huff GR, Rath NC, et al. Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens. Poult Sci. 2005;84(4):655-9.
  8. Indexed at, Google Scholar, Cross Ref

  9. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol. 2008;11(5):393-400.
  10. Indexed at, Google Scholar, Cross Ref

Get the App